A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS.

Trial Profile

A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Midostaurin
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 07 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top